Krystal Biotech will host an investor call on January 8, 2026, to discuss interim results from its KB407 cystic fibrosis study.
Quiver AI Summary
Krystal Biotech, Inc. announced it will hold an investor conference call and webcast on January 8, 2026, at 4:30 pm ET to provide an interim clinical update from its Phase 1 CORAL-1 study, which is assessing the efficacy of KB407 in cystic fibrosis patients. The update will highlight results from the highest dose cohort and include molecular evaluations of KB407 transduction and CFTR protein expression after inhaling KB407. Interested parties can access the live webcast online, and an archived version will be available on the company's website for at least 30 days. Krystal Biotech focuses on genetic medicines for unmet medical needs and has a growing pipeline in various therapeutic areas, including a recently approved gene therapy for dystrophic epidermolysis bullosa.
Potential Positives
- The upcoming investor conference call and webcast indicates transparency and engagement with stakeholders, showcasing the company's commitment to keeping investors informed about clinical developments.
- The interim clinical update on KB407, particularly focusing on the highest dose cohort, may provide significant insights into the therapy's efficacy and safety for cystic fibrosis, which could positively impact stock performance and investor confidence.
- Krystal Biotech’s existing commercial product, VYJUVEK®, demonstrates the company's capability in bringing innovative treatments to market, establishing a foundation for potential success with new products like KB407.
Potential Negatives
- The announcement of an interim clinical update could indicate that the company is facing challenges or delays in its clinical trial process, which may raise concerns among investors about the efficacy of KB407.
- The focus on a specific dose cohort may suggest that the results are not broadly applicable or significant across the entire trial population, potentially limiting investor confidence in the drug's overall effectiveness.
- The need for an interim update implies that the development of KB407 is still in a precarious stage, which could highlight uncertainty in the company's future prospects and impact stock performance.
FAQ
When is Krystal Biotech's investor conference call?
Krystal Biotech's investor conference call is scheduled for January 8, 2026, at 4:30 pm ET.
What will be discussed during the conference call?
The call will provide an interim clinical update from the CORAL-1 study evaluating KB407 in cystic fibrosis patients.
How can I access the investor conference call?
Investors can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53466.
Will there be an archived version of the call?
Yes, an archived version will be available on the Investors section of Krystal Biotech's website for at least 30 days.
What is KB407 being studied for?
KB407 is being studied as a treatment for cystic fibrosis in the multi-center, dose escalation Phase 1 CORAL-1 study.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$KRYS Insider Trading Activity
$KRYS insiders have traded $KRYS stock on the open market 62 times in the past 6 months. Of those trades, 0 have been purchases and 62 have been sales.
Here’s a breakdown of recent trading of $KRYS stock by insiders over the last 6 months:
- KRISH S KRISHNAN (President and CEO) has made 0 purchases and 31 sales selling 100,000 shares for an estimated $18,525,282.
- SUMA KRISHNAN (President, R&D) has made 0 purchases and 31 sales selling 100,000 shares for an estimated $18,525,168.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$KRYS Hedge Fund Activity
We have seen 151 institutional investors add shares of $KRYS stock to their portfolio, and 116 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC added 602,428 shares (+1743.1%) to their portfolio in Q3 2025, for an estimated $106,346,614
- BRAIDWELL LP removed 207,410 shares (-28.5%) from their portfolio in Q3 2025, for an estimated $36,614,087
- PRICE T ROWE ASSOCIATES INC /MD/ added 205,675 shares (+78.7%) to their portfolio in Q3 2025, for an estimated $36,307,807
- GOLDMAN SACHS GROUP INC removed 182,111 shares (-34.3%) from their portfolio in Q3 2025, for an estimated $32,148,054
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 170,858 shares (+72.9%) to their portfolio in Q3 2025, for an estimated $30,161,562
- MILLENNIUM MANAGEMENT LLC added 136,151 shares (+1083.8%) to their portfolio in Q3 2025, for an estimated $24,034,736
- CAPITAL WORLD INVESTORS removed 133,009 shares (-14.1%) from their portfolio in Q3 2025, for an estimated $23,480,078
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$KRYS Analyst Ratings
Wall Street analysts have issued reports on $KRYS in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 10/17/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/15/2025
- Chardan Capital issued a "Buy" rating on 08/05/2025
To track analyst ratings and price targets for $KRYS, check out Quiver Quantitative's $KRYS forecast page.
$KRYS Price Targets
Multiple analysts have issued price targets for $KRYS recently. We have seen 4 analysts offer price targets for $KRYS in the last 6 months, with a median target of $247.5.
Here are some recent targets:
- Yigal Nochomovitz from Citigroup set a target price of $309.0 on 01/06/2026
- Geulah Livshits from Chardan Capital set a target price of $220.0 on 11/04/2025
- Alec Stranahan from B of A Securities set a target price of $255.0 on 10/17/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $240.0 on 09/15/2025
Full Release
PITTSBURGH, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that it will host an investor conference call and webcast tomorrow, Thursday, January 8, 2026, at 4:30 pm ET, to disclose an interim clinical update from CORAL-1, the Company’s multi-center, dose escalation Phase 1 study evaluating KB407 in patients with cystic fibrosis. The interim clinical update will focus on results from patients in the highest dose cohort of CORAL-1 and include molecular assessments of KB407 transduction and wild-type cystic fibrosis transmembrane conductance regulator (CFTR) protein expression following inhaled administration of KB407.
Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53466 . For those unable to listen to the live webcast, an archived version will also be available on the Investors section of the Company’s website for at least 30 days.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK ® , the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com , and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACT
Investors and Media:
Stéphane Paquette
Krystal Biotech
[email protected]
